Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.08. | Foghorn: EPS übertrifft Schätzungen um 0,07 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
05.08. | Foghorn Therapeutics reports Q2 results | 3 | Seeking Alpha | ||
05.08. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
05.08. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
05.08. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | 163 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track... ► Artikel lesen | |
01.07. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | Citizens JMP reiterates Foghorn stock with $9 target | 2 | Investing.com | ||
14.05. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
14.05. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.05. | Foghorn Therapeutics erweitert Vorstand mit Biotech-Veteranen | 2 | Investing.com Deutsch | ||
01.05. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors | 1 | GlobeNewswire (USA) | ||
30.04. | Foghorn stock holds at $9 target, JMP affirms Market Outperform | 3 | Investing.com | ||
28.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | 1 | GlobeNewswire (USA) | ||
28.04. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.04. | JMP starts Foghorn stock with $9 target, sees major opportunity | 1 | Investing.com | ||
15.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
25.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting | 129 | GlobeNewswire (Europe) | - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical... ► Artikel lesen | |
06.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook | 149 | GlobeNewswire (Europe) | First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary... ► Artikel lesen | |
16.12.24 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | 195 | GlobeNewswire (Europe) | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 6,080 | 0,00 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
IMMUNOVANT | 16,075 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
KYMERA THERAPEUTICS | 56,29 | 0,00 % | Stifel bestätigt Kaufempfehlung für Kymera Therapeutics vor wichtigen Studiendaten | ||
ARCUTIS BIOTHERAPEUTICS | 21,240 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 37,485 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
DISC MEDICINE | 70,28 | 0,00 % | Mona Ashiya verlässt Verwaltungsrat von Disc Medicine - Gremium auf acht Mitglieder verkleinert | ||
ARVINAS | 9,750 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
JANUX THERAPEUTICS | 24,200 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
AMYLYX PHARMACEUTICALS | 13,480 | 0,00 % | BofA Securities hebt Kursziel für Amylyx-Aktie auf 16 US-Dollar an | ||
EVOTEC | 6,630 | -3,01 % | NetraMark Holdings, Evotec, Sartorius - Milliardengeschäfte im Blick! | Künstliche Intelligenz und Maschinelles Lernen sind mittlerweile in fast allen Branchen wichtige Schrittmacher. Wenn Pharmaunternehmen ein Medikament bis zur Marktreife entwickelt haben, sprudeln die... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 28,450 | 0,00 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
LENZ THERAPEUTICS | 48,600 | 0,00 % | Lenz Therapeutics platziert Aktienpaket im Wert von 80 Millionen US-Dollar | ||
QIAGEN | 40,995 | +0,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
XENETIC BIOSCIENCES | 10,370 | 0,00 % | Xenetic Biosciences Stock Surges 123% | ||
PRIME MEDICINE | 6,450 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen |